LYON, France, Nov. 6 /CNW/ - Sanofi Pasteur, the vaccines division of
sanofi-aventis Group, announced today positive results in the development of a
vaccine for the global prevention of dengue fever, one of the most widespread
tropical diseases. The results are being presented today at the American
Society of Tropical Medicine and Hygiene (ASTMH)'s 56th annual meeting held in
Philadelphia, Pennsylvania, USA.
These results have prompted Sanofi Pasteur to immediately expand ongoing
clinical trials in Asia and Latin America. Submission to health authorities
for registration is anticipated in 2012.
"Sanofi Pasteur made research for a vaccine against dengue fever one of
its top priorities by investing in the most promising technology and
dedicating top scientists to this lifesaving project," said Wayne Pisano,
President and Chief Executive Officer of Sanofi Pasteur. "Sanofi Pasteur's
goal is to make dengue fever a vaccine-preventable disease as quickly as
possible with a vaccine available to people living in endemic countries or
traveling to tropical destinations."
Immunization with Sanofi Pasteur's tetravalent dengue candidate vaccine
generated a sero-neutralizing antibody response against all four serotypes of
the virus responsible for dengue fever in 100 percent of adults who
participated in a trial in the United States.(1)
"Developing a dengue vaccine has been a major challenge for over a
decade, and we are very pleased with the breakthrough progress made by Sanofi
Pasteur with its tetravalent dengue vaccine," said Harold Margolis, MD,
Director of the Pediatric Dengue Vaccine Initiative (PDVI). "We believe this
moves the world closer to a dengue vaccine that will be available for people
who most need it."
Dengue fever is a mosquito-borne disease affecting up to 100 million
people each year and resulting in 24,000 deaths, mostly among children,
according to estimates from the World Health Organization (WHO).(2),(3)
Overall, the disease is a potential threat for close to half the world's
population. Dengue disease is often cyclical and causes spikes in demand on
local medical resources and places tremendous pressure on strained hospitals
and clinics located in endemic countries.
Dengue fever occurs mostly in tropical and subtropical countries and it
is spreading to new parts of the globe each year. For example, outbreaks
recently have been observed in Paraguay and the Middle East. In addition,
dengue affects countries such as Australia (Queensland) and the United States
(Puerto Rico, Texas-Mexico border, Hawaii and the US-affiliated Pacific
Islands). A substantial number of people traveling to endemic regions are also
infected each year.
Sanofi Pasteur's tetravalent dengue candidate vaccine is based on a new
technology incorporating the protein envelopes that provide immunity against
the four virus types responsible for dengue fever and the most severe forms of
the disease - dengue hemorrhagic fever and dengue shock syndrome.
Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York
(NYSE : SNY).
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided
more than a billion doses of vaccine in 2006, making it possible to immunize
more than 500 million people across the globe. A world leader in the vaccine
industry, Sanofi Pasteur offers the broadest range of vaccines protecting
against 20 infectious diseases. The company's heritage, to create vaccines
that protect life, dates back more than a century. Sanofi Pasteur is the
largest company entirely dedicated to vaccines. Every day, the company invests
more than EUR1 million in research and development. For more information,
please visit: www.sanofipasteur.com or www.sanofipasteur.us
Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include financial projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future events, operations, products and services, and statements
regarding future performance.
Forward-looking statements are generally identified by the words
"expects," "anticipates," "believes," "intends," "estimates," "plans" and
similar expressions. Although sanofi-aventis' management believes that the
expectations reflected in such forward-looking statements are reasonable,
investors are cautioned that forward-looking information and statements are
subject to various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of sanofi-aventis, that could cause
actual results and developments to differ materially from those expressed in,
or implied or projected by, the forward-looking information and statements.
These risks and uncertainties include those discussed or identified in the
public filings with the SEC and the AMF made by sanofi-aventis, including
those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for
the year ended December 31, 2006. Other than as required by applicable law,
sanofi-aventis does not undertake any obligation to update or revise any
forward-looking information or statements.
(1) Data analyzed by the WHO Flavivirus Laboratory Reference Center,
Mahidol University, Bangkok, Thailand
(2) State of the art of vaccine research and development. WHO/IVB/06.01
(3) World Health Organization, What is dengue? What is dengue
haemorrhagic fever? Available at:
For further information:
For further information: Sanofi Pasteur: Pascal Barollier, Media
Relations, Tel: + 33-(0)4-37-37-51-41, firstname.lastname@example.org;
Sanofi Pasteur: Len Lavenda, Media Relations US, Tel: (570) 839-4446,